These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29534674)

  • 1. Editorial: The Explosion of Biosimilars in Immune Mediated Chronic Inflammatory Diseases.
    Araujo FC; Fonseca JE; Goncalves J
    Curr Pharm Des; 2017; 23(44):6731-6732. PubMed ID: 29534674
    [No Abstract]   [Full Text] [Related]  

  • 2. The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases.
    Pentek M; Zrubka Z; Gulacsi L
    Curr Pharm Des; 2017; 23(44):6770-6778. PubMed ID: 29189134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The biosimilar road in inflammatory bowel disease: the right way?
    Fiorino G; Danese S
    Best Pract Res Clin Gastroenterol; 2014 Jun; 28(3):465-71. PubMed ID: 24913385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper.
    Fiorino G; Girolomoni G; Lapadula G; Orlando A; Danese S; Olivieri I;
    Autoimmun Rev; 2014 Jul; 13(7):751-5. PubMed ID: 24657898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars in inflammatory bowel disease.
    Moore GT
    Med J Aust; 2016 Oct; 205(7):294-5. PubMed ID: 27681963
    [No Abstract]   [Full Text] [Related]  

  • 6. Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD).
    Franchimont D; Ferrante M; Louis E; De Vos M; Dewit O; Van Hootegem P; Moreels T; Liefferinckx C; Bossuyt P; Baert F; Rahier JF; Vermeire S
    Acta Gastroenterol Belg; 2018; 81(1):49-53. PubMed ID: 29562378
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases.
    Felice C; Pugliese D; Armuzzi A
    Expert Opin Biol Ther; 2019 Oct; 19(10):967-969. PubMed ID: 30616459
    [No Abstract]   [Full Text] [Related]  

  • 8. Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases.
    Somers M; Bossuyt P; Ferrante M; Peeters H; Baert F
    J Crohns Colitis; 2020 Jun; 14(5):680-685. PubMed ID: 31875891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
    Danese S; Fiorino G; Raine T; Ferrante M; Kemp K; Kierkus J; Lakatos PL; Mantzaris G; van der Woude J; Panes J; Peyrin-Biroulet L
    J Crohns Colitis; 2017 Jan; 11(1):26-34. PubMed ID: 27927718
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD).
    Viscido A; Buda A; Caprioli F; Principi M; Daperno M; Armuzzi A
    Dig Liver Dis; 2020 Aug; 52(8):928-930. PubMed ID: 32616462
    [No Abstract]   [Full Text] [Related]  

  • 11. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
    Gecse KB; Cumming F; D'Haens G
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Assessment and Monitoring of Antibody Responses to Biosimilars in Chronic Inflammatory Diseases.
    Detrez I; Gils A
    Curr Pharm Des; 2017; 23(44):6739-6745. PubMed ID: 29189133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease.
    Patil SA; Bhat S; Limdi JK; Farraye FA; Cross RK
    Inflamm Bowel Dis; 2022 Dec; 28(12):1915-1923. PubMed ID: 35353189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Biosimilars in Patient Access to Therapeutic Antibodies for Immune Mediated Inflammatory Diseases.
    Chapman MA; Charles D; Loaiza-Bonilla A
    Curr Pharm Des; 2017; 23(44):6779-6783. PubMed ID: 29189136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.
    Argüelles Arias F; Hinojosa Del Val J; Vera Mendoza I
    Rev Esp Enferm Dig; 2018 Jun; 110(6):407. PubMed ID: 29527903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars in IBD: hope or expectation?
    Gecse KB; Khanna R; van den Brink GR; Ponsioen CY; Löwenberg M; Jairath V; Travis SP; Sandborn WJ; Feagan BG; D'Haens GR
    Gut; 2013 Jun; 62(6):803-7. PubMed ID: 23503043
    [No Abstract]   [Full Text] [Related]  

  • 18. Position statement on the use of biosimilars in inflammatory bowel disease.
    Burri E; Juillerat P; Maillard MH; Manz M; Michetti P; Mottet C; Rogler G; Zahnd N; Vavricka S
    Swiss Med Wkly; 2019 Dec; 149():w20148. PubMed ID: 31800086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar therapy for inflammatory bowel disease.
    Avendaño-Solá C; Panés J; Calvo G
    Rev Esp Enferm Dig; 2014 Jan; 106(1):65-6. PubMed ID: 24689722
    [No Abstract]   [Full Text] [Related]  

  • 20. Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.
    Patel D; Park KT
    J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):134-136. PubMed ID: 28319603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.